Bio-Rad Laboratories, Inc.Class A (BIO) is a publicly traded Healthcare sector company. As of September 16, 2026, BIO trades at $380.21 with a market cap of $9.85B and a P/E ratio of 45.96. BIO moved +0.21% today. Year to date, BIO is +24.76%; over the trailing twelve months it is +34.90%. Its 52-week range spans $211.43 to $396.23. Analyst consensus is moderatebuy with an average price target of $350.00. Rallies surfaces BIO's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies tracks politician and congressional stock disclosures for BIO, including purchases, sales, transaction dates, owners, and reported trade amounts when available.
| Metric | Value |
|---|---|
| Price | $380.21 |
| Market Cap | $9.85B |
| P/E Ratio | 45.96 |
| EPS | $8.23 |
| Dividend Yield | 0.00% |
| 52-Week High | $396.23 |
| 52-Week Low | $211.43 |
| Volume | 39.20K |
| Avg Volume | 0 |
| Revenue (TTM) | $2.59B |
| Net Income | $222.40M |
| Gross Margin | 51.90% |
3 analysts cover BIO: 0 strong buy, 1 buy, 2 hold, 0 sell, 0 strong sell. Consensus rating is moderatebuy. Average price target: $350.00.